片仔癀：创新药PZH2108片Ⅱa期临床试验完成首例受试者入组 尚未有同靶点同适应症的药物获批上市

Core Viewpoint - The company Pianzaihuang (片仔癀) has announced the successful enrollment of the first subject in the Phase IIa clinical trial for its innovative chemical drug PZH2108, aimed at treating cancer-related pain [2]. Group 1: Drug Development - PZH2108 has completed the enrollment of the first subject in its Phase IIa clinical trial [2]. - The total research and development investment for PZH2108 has reached approximately 61 million yuan [2]. - As of the announcement date, no other companies have obtained production licenses for this product, and there are no approved drugs targeting the same indication as PZH2108 [2].